FDA Reels In Golden Caviar For Fishy Skin-Care Claims
This article was originally published in The Rose Sheet
Skin-lightening claims appear to be on FDA's radar as it continues its crackdown on overreaching cosmetic marketing, issuing a warning letter to Golden Caviar Skin Care for statements promoting a whitening serum and cream, among other offerings. The company's Caviar Lifting and Firming Serum with Zinc also is an unapproved drug, based on claimed benefits including wound healing and acne relief, the agency says.
You may also be interested in...
Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.
In a Feb. 12 warning letter, just the descriptors for two L’Oreal/La Roche-Posay products – a “Localized Redness Intensive Serum” and “Concentrated Dark Spot Correcting Serum” – are cited by FDA as evidence that the products are intended for use as drugs. The warning raises questions about the viability of those categories for cosmetics firms intent on staying off FDA’s radar.
Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top